About this trial
The purpose of this study is to identify and evaluate oral fluid testing as a biologic measure of cannabis use days that can be assessed remotely. The researchers will conduct this fully virtual study among a community sample of 200 individuals aged 18-30 years who have used cannabis at least 1 time per week on average in the past 30 days. Participants will complete oral fluid (saliva) tests, urine tests, and Timeline Follow-back interviews (self-report) that indicate their recent cannabis use (delta-9-THC). Participants will present for 3 virtual study visits across \~3-4 weeks and be asked to complete activities in between: Study Visit 1 (Day 0; informed consent, baseline survey, TLFB interview), Study Visit 2 (\~Day 7; TLFB interview, urine testing), 6 days of at-home videorecorded oral fluid testing, Study Visit 3 (\~Day 21; TLFB interview, urine test, oral fluid test, survey, interview).
Eligibility criteria
Qualifiers
Age 18 to 30 years
Cannabis use on >=1x/week in the past 30 days
Ownership of a portable device that is capable of videoconference and videorecording (i.e., smartphone, tablet computer, or laptop computer)
Ability to read and speak English
Disqualifiers
None
Trial design
Treatments tested in this trial
- Biologic testing for THC
Treatment groups
Sponsors and collaborators
Boston Children's Hospital
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator